Targets 17 , 437448 (2013)
Patients received semaglutide treatment (0.25 mg/week initially, escalated to 0.5 mg/week) for 12 weeks
Musculoskeletal Muscle pain, fibromyalgia, increased osteopenia, osteoporosis, weakness, and migratory arthritis (joint pain)
In the main per-protocol analyses, participants were followed from the index date to first mutually exclusive incidence of SIS, discontinuation of study drug (defined as more than 60 days without drug supply), initiation of other study drug, or switch to other glucose-lowering drug (defined as filling a prescription for any glucose-lowering drug other than the baseline treatment or metformin and not refilling the assigned drug for 60 days), death, or end of follow-up
Talk to your medical director and lawyer before adding any new therapy
Advanced blends combine L-carnitine with other nutrients in products across energy, recovery and metabolic support categories